Cipla Health Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions, including Asia, Africa, and Europe. Founded in 1935, Cipla has established itself as a leader in the development and manufacturing of a diverse range of healthcare products, including prescription medications, over-the-counter drugs, and wellness solutions. The company is renowned for its commitment to innovation, particularly in respiratory, cardiovascular, and anti-infective therapies. Cipla's unique approach to affordable healthcare has positioned it as a trusted name in the market, with notable achievements in expanding access to essential medicines globally. With a strong focus on quality and sustainability, Cipla Health Limited continues to make significant strides in improving health outcomes for patients worldwide.
How does Cipla Health Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cipla Health Limited's score of 38 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cipla Health Limited, headquartered in India, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Cipla Limited, which provides emissions data cascaded from its parent organisation. However, no absolute emissions figures or reduction targets have been disclosed for Cipla Health Limited itself. Cipla Limited, as the source of cascaded data, is involved in various climate initiatives, including participation in the CDP (Carbon Disclosure Project) at a cascade level of 1. Despite the absence of specific emissions data or reduction commitments for Cipla Health Limited, the parent company’s engagement in climate action reflects a broader commitment to sustainability within the industry. As of now, Cipla Health Limited has not outlined any specific climate pledges or reduction targets, indicating a potential area for future development in their environmental strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 48,146,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 236,358,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Cipla Health Limited's Scope 3 emissions, which increased by 10% last year and increased by approximately 10% since 2024, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 53% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cipla Health Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.